Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Good morning all,
Whilst news has always seemed ‘imminent’ (how far can the definition be stretched), it does seem attractive that the buy in price now is similar to what it was months back. I’m taking a guess that there will be material news this autumn per what RM was saying earlier in the year.
GLA,
Leaf
Anyone else having trouble joining?I’m on the page below on a mobile but there is no link to stream/event: https://www.lsegissuerservices.com/spark/Synairgen/events/1cd87eb6-5e01-4e1a-b3bd-f8288bbb6b5b
From some research it shows no change to Activ 2 or 3 on the web (with regards to SNG001). WF - fair point about selection criteria.
Whilst Activ 2 May surprise us with some good results, Activ 3 seems to be where we would be most effective.
Atb,
Leaf
Activ 2 could well mirror our ‘at home’ trial arm, don’t we think?
If the US action for SNG switches to hospitalized patients then we will show more efficacy, but in the meantime it seems likely that Activ 2 won’t be the seal of approval stateside that we have been hoping for.
I’d guess we could see 120s again if that is the case, before a bigger rise as the penny drops and word spreads. I’m prepare to be wrong but I am trading it that way. Anyone doing the same, or are all holding holding holding?
Atb,
Leaf
Thanks for the responses. There are lots of good points raised.
It has been a long journey since April-ish last year, and I don’t subscribe to the theory that we are being bought out tomorrow/next week/this fortnight.
I think we’ll complete P3, with fantastic results, and then perhaps a buyout or JV once approval is on the table. RM knows that is where the money is and they have put in the hard yards to get to where they are.
If I am wrong re the cash raise this week then I’m back in again, simple as that.
Atb,
Leaf
I took half off the table this afternoon. Why?
A nagging fear that history might repeat itself re a placing. I know we are funded for P3 etc.
The six month period has passed since the last raise. AGM round the corner, no offer on the table yet, might they want to cash raise?
The last flurry upward in price back in the autumn preceded a placing. I know the picture is different now, and welcome constructive thoughts on this topic.
Really not a de-ramp, before Oak scrambles to his keyboard. It is Friday evening and markets are a long way away.
Atb,
Leaf
It’s lovely to see the retrace back to the 150/200 zone.
What is encouraging is that there is so much more news to follow - all speculative but possible: production levels, Activ progression, EUA, JV, therapeutic task force, long covid, copd etc etc.
100-160 on the fact it works on the variants? Great! Plenty more news in the tank.
Atb,
Leaf
I am glad we have already engaged with the FDA and been granted fast-track status.
Reading between the lines in the following link, it seems they are reducing new applications for EUA - the link is about vaccines, but we could see a similar pattern with treatments in due course.
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-may-25-2021
Atb,
Leaf
I think there is a chance we’ll see an article or two from Prof Holgate in the next week or so. He has been in the papers already earlier this year and the in vitro studies to back up the theory of ‘virus agnostic’ is of general interest, imo.
Things are pointing back in the right direction.
Atb,
Leaf
I’m back in on the expectation that they’ll release stock levels and production details in the next month or so. (Might be wrong, but it is a hunch).
I feel the messaging is getting a little clearer and sentiment will shift back and those that have been out will buy back in (like I have done).
ATB,
Leaf
Hey Lima,
I think investors are waiting on some hard figures about production levels and current stock. This was not in his interview (but would probably need an RNS any way).
From my perspective, it is worrying that he clearly feels bad about not replying to each and every email from Joe Public.
I would appeal to those that read this board to stop emailing the man, let him get on with doing his job. There are only so many hours in the day. Imagine a pre-order, and see that it is more likely to happen if you don’t email the CEO once a week.
Leaf
November’s drop was in relation to vaccine news (outside the company’s sphere of influence), the latest drop is for a c0cktail of reasons within the company’s sphere of influence.
That is why there is no hard bounce as yet. Belief is shaken on the back of what SNG have released.
Best,
Leaf
Some late reporting going on here?
So much SP change and it can’t all be PI can it?
Perhaps an II is filling their boots on the sly (SP doesn’t suggest it) or perhaps have offloaded but with no TR1.
Good weekend all,
Leaf
TLW - the below was more in context of takeover rather than production or a JV, but you may find it interesting:
Synairgen has a stated strategy for a standalone future and will continue to pursue that in order to create shareholder value.
That is a snippet of corres I had with Numis.
RM’s comments have been so vague that they can be read any which way, in my humble opinion.
This board varies between ‘don’t sell out too cheap’ to ‘we’ve always known we need a big pharmaceutical to get this out there’ depending on where the SP is on any given day.
Leaf
Would current stock levels and production rate not constitute market sensitive data? We don’t need a day by day update but RM should update the market, let alone because investors paid for increased production via the fundraiser.
100k/month target does not constitute an update.
ATB,
Leaf